Literature DB >> 16480664

Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.

Apurva A Desai1, Walter M Stadler.   

Abstract

The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.

Entities:  

Year:  2006        PMID： 16480664     DOI： 10.1007/s11934-006-0033-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  45 in total

Review 1.  Contemporary approach to the classification of renal epithelial tumors.

Authors:  V E Reuter; J C Presti
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

2.  Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.

Authors:  Arthur R Salomon; Scott B Ficarro; Laurence M Brill; Achim Brinker; Qui T Phung; Christer Ericson; Karsten Sauer; Ansgar Brock; David M Horn; Peter G Schultz; Eric C Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-09       Impact factor: 11.205

3.  Gene expression profiling identifies molecular subtypes of gliomas.

Authors:  Ruty Shai; Tao Shi; Thomas J Kremen; Steve Horvath; Linda M Liau; Timothy F Cloughesy; Paul S Mischel; Stanley F Nelson
Journal:  Oncogene       Date:  2003-07-31       Impact factor: 9.867

4.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

5.  Randomized discontinuation design: application to cytostatic antineoplastic agents.

Authors:  Gary L Rosner; Walter Stadler; Mark J Ratain
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

6.  Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.

Authors:  Kevin J Turner; John W Moore; Adam Jones; Claire F Taylor; Darren Cuthbert-Heavens; Cheng Han; Russell D Leek; Kevin C Gatter; Patrick H Maxwell; Peter J Ratcliffe; David Cranston; Adrian L Harris
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Authors:  Beverly Drucker; Jennifer Bacik; Michelle Ginsberg; Stephanie Marion; Paul Russo; Madhu Mazumdar; Robert Motzer
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 9.  Indications for imatinib mesylate therapy and clinical management.

Authors:  François Guilhot
Journal:  Oncologist       Date:  2004

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  3 in total

Review 1.  Therapy-induced senescence in cancer.

Authors:  Jonathan A Ewald; Joshua A Desotelle; George Wilding; David F Jarrard
Journal:  J Natl Cancer Inst       Date:  2010-09-21       Impact factor: 13.506

2.  PRMT5 as a druggable target for glioblastoma therapy.

Authors:  Yeshavanth Kumar Banasavadi-Siddegowda; Alessandra M Welker; Min An; Xiaozhi Yang; Wei Zhou; Guqin Shi; Jaime Imitola; Chenglong Li; Sigmund Hsu; Jiang Wang; Mitch Phelps; Jianying Zhang; Christine E Beattie; Robert Baiocchi; Balveen Kaur
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

3.  Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.

Authors:  Sung Han Kim; Weon Seo Park; Sun Ho Kim; Jae Young Joung; Ho Kyung Seo; Kang Hyun Lee; Jinsoo Chung
Journal:  Cancer Res Treat       Date:  2016-01-28       Impact factor: 4.679
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.